Consensus statement for non-hormonal-based treatments for menopausal symptoms.

about

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

Item

http://www.wikidata.org/entity/Q47338438

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

@en

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

@nl

type

Item

label

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

@en

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

@nl

prefLabel

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

@en

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

@nl

P1476

Consensus statement for non-hormonal-based treatments for menopausal symptoms.

@en

P2093

Jane Woyka

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study.

Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

FDA approval of paroxetine for menopausal hot flushes.

Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.

Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis.

Duration of menopausal hot flushes and associated risk factors

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.

A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.

P304

71-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2053369117711646

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28643614

http://www.w3.org/2001/XMLSchema#string